Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04023799
Other study ID # MTN-045
Secondary ID UM1AI068633UM1AI
Status Completed
Phase
First received
Last updated
Start date January 21, 2020
Est. completion date November 5, 2020

Study information

Verified date October 2022
Source Microbicide Trials Network
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

MTN-045 is a cross-sectional study that will utilize questionnaires, including Discrete-Choice Experiments (DCE) and joint decision tasks, to assess couples' preferences related to dual purpose prevention (DPP) products that could be used to prevent unintended pregnancies and HIV infection. Post-survey explanatory in-depth interviews (IDIs) will be conducted with a subset of participants to explore DPP product-related decisions..


Description:

MTN-045 is a cross-sectional study that will utilize questionnaires, including DCEs and joint decision tasks, and IDIs to assess heterosexual couples' preferences related to DPP products that could be used to prevent unintended pregnancies and HIV infection. One main goal of the study is to determine heterosexual couples' preferences for a DPP product to inform product delivery and future product design to maximize uptake and willingness to use among sub-Saharan African heterosexual couples. Another main goal of the study is to assess the level of influence of the male partner on a woman's preferences for a DPP product and on her decision-making process regarding product preferences and use. The MTN-045 study population will consist of approximately 400 heterosexual sub-Saharan African couples of reproductive age who have been in a relationship for ≥ 3 months and are interested in contraception and/or HIV prevention. Women who are currently using contraceptives as well as those not using contraceptives will be eligible. Couples who are living together as well as those not living together will be eligible. All participants will complete survey questionnaires, first separately from their partner, then followed by a joint couples' decision task. Up to 80 participants, i.e., one or both partners from a subset of up to 40 couples, will be selected to complete an IDI.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date November 5, 2020
Est. primary completion date November 5, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: Each member of the couple must meet all of the following criteria to be eligible for inclusion in the study, and both members of the couple must be willing and eligible for the couple to enroll: 1. Able and willing to provide written informed consent in one of the study languages. 2. Able and willing to complete the required study procedures. 3. Currently in a heterosexual relationship (living together or not) for at least 3 months (by self-report) with the other member of the couple. 4. At time of Enrollment, expressed interest in contraception and/or HIV prevention (by self-report). For female partner: 5. Between the ages of 18 to 40 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs). 6. HIV negative (by self-report). For male partner: 7. Aged 18 years or older at Enrollment, verified per site SOPs. Exclusion Criteria: Potential participants who meet the following criteria will be excluded from the study along with their partner: 1. Has any significant medical condition or other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe (including risk for IPV as a result of study participation), complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Uganda Makerere University - Johns Hopkins University (MU-JHU) Research Kampala
Zimbabwe Zengeza Clinical Research Site Harare

Sponsors (4)

Lead Sponsor Collaborator
Microbicide Trials Network Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)

Countries where clinical trial is conducted

Uganda,  Zimbabwe, 

References & Publications (1)

Minnis AM, Etima J, Musara P, Browne EN, Mutero P, Kemigisha D, Mgodi NM, Nakabiito C, Shapley-Quinn MK, Stoner MCD, Hartmann M, Macagna N, Piper J, van der Straten A. Couples' Preferences for "2 in 1" Multipurpose Prevention Technologies to Prevent Both — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Salient relationship characteristics, norms and communication factors that influenced participants' decision-making process Survey questionnaires 12-15 months during Q2 2019/Q4 2020
Other Differences in product preferences, when comparing individual to couples' choices, that characterize the male partner's role in females' preferences Discrete-Choice Experiments (DCE) 12-15 months during Q2 2019/Q4 2020
Other Likelihood of using each DPP product, overall and by subgroup, as estimated through analysis of DCE data Discrete-Choice Experiments (DCE) 12-15 months during Q2 2019/Q4 2020
Primary Attributes of a DPP product that influence preferences among heterosexual couples Survey questionnaires 12-15 months during Q2 2019/Q4 2020
Primary Differences in DPP product attribute preferences when comparing individual to couples' choices (e.g., woman's individual preferences vs. preferences indicated through the joint couples decision task) Discrete-Choice Experiments (DCE) 12-15 months during Q2 2019/Q4 2020
Secondary Salient relationship-based and decision-making factors that influence DPP product interest and preferences Survey questionnaires 12-15 months during Q2 2019/Q4 2020
Secondary Differences in attributes salient to preferences by sociodemographic factors such as age and parity that may reflect lifecourse stage Survey questionnaires 12-15 months during Q2 2019/Q4 2020
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1